A preliminary study on the synthetic lethal effect of berberine and olaparib on pancreatic cancer cells and its mechanism [PDF]
E3S Web of Conferences, 2021 Pancreatic cancer is a kind of malignant tumor with high mortality rate. Early operation and late chemoradiotherapy are the treatment criteria, but the prognosis is still poor.
Zhang Chengyong +9 more
doaj +1 more source
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. [PDF]
PLoS ONE, 2014 AIM OF THE STUDY:To evaluate the frequency of MRE11/RAD50/NBS1 (MRN)-complex loss of protein expression in endometrial cancers (EC) and to determine whether loss of MRE11 renders the cancer cells sensitive to Poly(ADP-ribose) polymerase (PARP)-inhibitory
Romana Koppensteiner +11 more
doaj +1 more source
Effects of alcohol and PARP inhibition on RNA ribosomal engagement in cortical excitatory neurons
Frontiers in Molecular Neuroscience, 2023 We report on the effects of ethanol (EtOH) and Poly (ADP-ribose) polymerase (PARP) inhibition on RNA ribosomal engagement, as a proxy for protein translation, in prefrontal cortical (PFC) pyramidal neurons.
Harish R. Krishnan +10 more
doaj +1 more source
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. [PDF]
, 2017 Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature.
Berry, Don +20 more
core +2 more sources
GBM radiosensitizers: dead in the water…or just the beginning? [PDF]
, 2017 The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control.
Bindra, Ranjit S. +3 more
core +1 more source
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
Therapeutic Advances in Medical Oncology, 2017 Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Tarra Evans, Ursula Matulonis
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2021 Background Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions.
Dorota Wyczechowska +12 more
doaj +1 more source
PARP Inhibitors in Ovarian Cancer [PDF]
Recent Patents on Anti-Cancer Drug Discovery, 2018 Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical ...
Mittica, Gloria +6 more
openaire +3 more sources
PARP Inhibitors in Pancreatic Cancer
The Cancer Journal, 2021 Abstract Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow.
Timothy J. Brown, Kim A. Reiss
openaire +3 more sources